Discontinuation report EGRIFTA
Report ID | 170025 |
Drug Identification Number | 02438712 |
Brand name | EGRIFTA |
Common or Proper name | Tesamorelin for injection |
Company Name | THERATECHNOLOGIES INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | TESAMORELIN |
Strength(s) | 1MG |
Dosage form(s) | POWDER FOR SOLUTION KIT |
Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
Packaging size | 60 vials containing (each) 1 mg of tesamorelin |
ATC code | H01AC |
ATC description | ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2022-09-30 |
Actual discontinuation date | |
Remaining supply date | 2022-09-30 |
Discontinuation status | To be discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 2015 PEEL STREET MONTREAL, QUEBEC CANADA H3A 1T8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v2 | 2022-09-22 | French | Compare |
v1 | 2022-09-22 | English | Compare |
Showing 1 to 2 of 2